Emerald Bioscience Inc. (OTCMKTS:EMBI – Get Free Report) shares traded down 6.6% on Tuesday . The company traded as low as $0.8026 and last traded at $0.8136. 197,253 shares were traded during mid-day trading, a decline of 99% from the average session volume of 14,236,620 shares. The stock had previously closed at $0.8712.
Emerald Bioscience Stock Down 6.8%
The firm has a market cap of $194.41 million, a price-to-earnings ratio of -9.07 and a beta of 0.43. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.43. The stock has a fifty day moving average price of $0.76.
Emerald Bioscience Company Profile
Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.
See Also
- Five stocks we like better than Emerald Bioscience
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Emerald Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emerald Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
